

William Hope

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/568486/william-hope-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182
papers

12,601
citations

50
h-index

109
g-index

195
ext. papers

14,573
ext. citations

7.2
avg. IF

6.25
L-index

#	Paper	IF	Citations
182	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 , 77, 466-473	5.1	0
181	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.. <i>New England Journal of Medicine</i> , 2022 , 386, 1109-1120	59.2	13
180	Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0218121	5.9	
179	Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 ,	5.1	1
178	Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	1
177	Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0029321	5.9	5
176	Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2252-2259	5.1	6
175	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	3
174	Optimising antimicrobial use in humans - review of current evidence and an interdisciplinary consensus on key priorities for research. <i>Lancet Regional Health - Europe, The</i> , 2021 , 7, 100161		14
173	Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by <i>Talaromyces marneffe</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0063621	5.9	1
172	Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. <i>Paediatric Drugs</i> , 2021 , 23, 465-484	4.2	3
171	Cryptococcal meningoencephalitis: time for action. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e259-e271	25.5	5
170	An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. <i>ELife</i> , 2021 , 10,	8.9	1
169	Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with <i>Schistosoma japonicum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
168	Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. <i>Critical Care</i> , 2020 , 24, 55	10.8	15
167	Setting Our Sights on Infectious Diseases. <i>ACS Infectious Diseases</i> , 2020 , 6, 3-13	5.5	9
166	Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 65,	5.9	5

165	Metallo- β -Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	44
164	Pharmacodynamics of the Novel Metallo- β -Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	8
163	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 65,	5.9	4
162	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum- β -Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	8
161	CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 991-996	5.1	11
160	Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	8
159	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	6
158	Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	24
157	Population Pharmacokinetics of Anidulafungin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
156	A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. <i>Wellcome Open Research</i> , 2019 , 4, 8	4.8	12
155	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2326-2334	5.1	21
154	Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
153	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1648-1655	5.1	5
152	Generating Robust and Informative Nonclinical and Bacterial Infection Model Efficacy Data To Support Translation to Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	69
151	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019 , 68, 393-401	11.6	47
150	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 999-1014	15.9	57
149	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019 , 10,	7.8	22
148	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	3

147	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	15
146	Antifungal Dosing Considerations for Term and Preterm Infants 2019 , 185-191		
145	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 757-763	5.1	26
144	A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 992-998	3.4	18
143	Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 315-321	3.2	6
142	Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 1177-1183	9.5	13
141	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	5
140	Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1340-1347	5.1	22
139	Delivering precision antimicrobial therapy through closed-loop control systems. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 835-843	5.1	23
138	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1091-1092	2.8	3
137	Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	26
136	Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 449-457	6.1	9
135	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non- <i>albicans</i> spp. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1449-1459	2.8	4
134	Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2544-2550	3.8	15
133	Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	5
132	AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018 , 19, 649	2.8	26
131	Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 580-585	3.4	2
130	Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	7

129	Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 803-815	5.5	8
128	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	18
127	The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. <i>Drugs</i> , 2017 , 77, 941-950	12.1	8
126	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1557-1563	11.6	35
125	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	24
124	Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	14
123	Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. <i>Journal of Infection</i> , 2017 , 74, 320-324	18.9	1
122	Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. <i>Current Opinion in Pharmacology</i> , 2017 , 36, 114-123	5.1	39
121	Pharmacodynamics of teicoplanin against MRSA. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3382-3389	33.9	26
120	Combination therapy for carbapenemase-producing Entero-bacteriaceae: INCREMENT-al effect on resistance remains unclear. <i>Lancet Infectious Diseases</i> , 2017 , 17, 899-900	25.5	3
119	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	52
118	Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
117	Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, i12-i18	5.1	74
116	Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	37
115	Pharmacodynamics of the Orotomides against : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. <i>MBio</i> , 2017 , 8,	7.8	36
114	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2342-2350	5.1	17
113	Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3168-3178	5.1	13
112	Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. <i>Critical Care</i> , 2016 , 20, 343	10.8	29

111	F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 12809-12814	11.5	121
110	Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4568-76	5.9	41
109	Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. <i>Drugs</i> , 2016 , 76, 485-500	12.1	208
108	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 992-1002	5.1	25
107	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet, The</i> , 2016 , 387, 760-9	40	501
106	Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2718-26	5.9	31
105	Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 278-87	5.9	20
104	Antifungal Pharmacokinetics and Pharmacodynamics. <i>Methods in Pharmacology and Toxicology</i> , 2016 , 369-383	1.1	
103	Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1885-91	5.1	24
102	Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 887-97	3.8	14
101	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2336-42	5.9	25
100	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2234-40	5.1	10
99	Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 7340-7346	5.9	28
98	Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3008-3019	5.1	14
97	Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2735-45	5.9	20
96	Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 905-13	5.9	25
95	Therapeutic drug monitoring of the β -lactam antibiotics: what is the evidence and which patients should we be using it for?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3178-83	5.1	88
94	Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5602-10	5.9	72

93	Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 136-53 ⁹	3.9	93
92	Linezolid underexposure in a patient co-treated with venlafaxine. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1285-6	2.8	7
91	Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2854-61	5.1	52
90	Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. <i>Current Opinion in Pharmacology</i> , 2015 , 24, 128-34	5.1	10
89	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1183-93	5.9	42
88	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1194-201	5.9	32
87	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 276	2.8	21
86	Achieving target voriconazole concentrations more accurately in children and adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3090-7	5.9	48
85	Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1411-7	5.9	19
84	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1495-502 ^{5.1}	5.1	43
83	Tissue penetration of antifungal agents. <i>Clinical Microbiology Reviews</i> , 2014 , 27, 68-88	34	234
82	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , 2014 , 14, 498-509	25.5	534
81	Changes in the incidence of candidiasis in neonatal intensive care units. <i>Pediatrics</i> , 2014 , 133, 236-42	7.4	90
80	Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1162-76	5.1	404
79	Population pharmacokinetics of teicoplanin in children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6920-7	5.9	21
78	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. <i>Lancet Oncology</i> , 2014 , 15, e327-40	21.7	274
77	EUCAST technical note on <i>Candida</i> and micafungin, anidulafungin and fluconazole. <i>Mycoses</i> , 2014 , 57, 377-9	5.2	33
76	Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4094-102	5.9	52

75	An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i> : the role of azole resistance. <i>Medical Mycology</i> , 2014 , 52, 311-9	3.9	33
74	Pulmonary penetration of piperacillin and tazobactam in critically ill patients. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 438-48	6.1	31
73	1210A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S36-S37	1	1
72	First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 1005-18	6.2	12
71	Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. <i>MBio</i> , 2014 , 5, e00725-13	7.8	19
70	How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 79, 441-7	2.9	45
69	Gene expression profiles of human dendritic cells interacting with <i>Aspergillus fumigatus</i> in a bilayer model of the alveolar epithelium/endothelium interface. <i>PLoS ONE</i> , 2014 , 9, e98279	3.7	20
68	Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2793-800	5.9	46
67	Invasive fungal infections. <i>Clinical Medicine</i> , 2013 , 13, 507-10	1.9	19
66	Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp. <i>Drug Resistance Updates</i> , 2013 , 16, 81-95	23.2	98
65	Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 911-26	5.5	68
64	Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 1381-95	3.8	26
63	Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5811-9	5.9	51
62	Pharmacokinetics and pharmacodynamics of anidulafungin for experimental <i>Candida</i> endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 281-8	5.9	14
61	Software for dosage individualization of voriconazole for immunocompromised patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1888-94	5.9	33
60	In vitro susceptibility of <i>Aspergillus fumigatus</i> to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5778-80	5.9	58
59	EUCAST technical note on voriconazole and <i>Aspergillus</i> spp. <i>Clinical Microbiology and Infection</i> , 2013 , 19, E278-80	9.5	63
58	Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. <i>Mycoses</i> , 2012 , 55, 33-38	5.2	2

57	EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). <i>Clinical Microbiology and Infection</i> , 2012 , 18, E246-7	9.5	277
56	EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. <i>Clinical Microbiology and Infection</i> , 2012 , 18, E248-50	9.5	101
55	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 38-52	9.5	206
54	Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality. <i>Journal of Infection</i> , 2012 , 65, 350-6	18.9	21
53	Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5303-8	5.9	22
52	Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5180-5	5.9	24
51	Posaconazole: the case for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 72-6	3.2	27
50	Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4087-94	5.9	61
49	Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2435-42	5.9	98
48	Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4146-53	5.9	11
47	Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 759-65	5.5	49
46	Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 708-14	5.9	31
45	Population pharmacokinetics of voriconazole in adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 526-31	5.9	76
44	Optimizing micafungin dosing in children. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 1211-2; author reply 1212	3.4	4
43	The management of Candida infections in preterm neonates and the role of micafungin. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2011 , 24 Suppl 2, 24-7	2	15
42	Fluconazole loading dose pharmacokinetics and safety in infants. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 375-8	3.4	82
41	EUCAST technical note on Amphotericin B. <i>Clinical Microbiology and Infection</i> , 2011 , 17, E27-9	9.5	47
40	EUCAST technical note on posaconazole. <i>Clinical Microbiology and Infection</i> , 2011 , 17, E16-7	9.5	13

39	EUCAST technical note on anidulafungin. <i>Clinical Microbiology and Infection</i> , 2011 , 17, E18-20	9.5	50
38	Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 702-7	6.1	52
37	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. <i>Current Fungal Infection Reports</i> , 2011 , 5, 128-134	1.4	5
36	Disseminated Candidiasis caused by <i>Candida albicans</i> with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3075-83	5.9	47
35	Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1324-32	7	87
34	Optimizing management of invasive mould diseases. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66 Suppl 1, i45-53	5.1	32
33	Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4782-8	5.9	168
32	Pharmacodynamics of echinocandins against <i>Candida glabrata</i> : requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4880-7	5.9	37
31	Safety and pharmacokinetics of repeat-dose micafungin in young infants. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 93-9	6.1	90
30	Population pharmacokinetics of micafungin in neonates and young infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2633-7	5.9	96
29	Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3432-41	5.9	43
28	The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β -glucan and consequences of delayed antifungal therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4879-86	5.9	59
27	Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1383-91	11.6	105
26	Therapy for fungal diseases: opportunities and priorities. <i>Trends in Microbiology</i> , 2010 , 18, 195-204	12.4	225
25	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 3453-61	5.9	72
24	Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. <i>Clinical Infectious Diseases</i> , 2009 , 49, 928-30	11.6	91
23	Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2382-91	5.9	81
22	Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. <i>Clinical Microbiology and Infection</i> , 2009 , 15, 602-12	9.5	36

21	Aspergillus 2009 , 271-296		3
20	Pharmacokinetics of an elevated dosage of micafungin in premature neonates. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 412-5	3.4	112
19	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1813-21	11.6	3744
18	Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 4121-9	5.9	46
17	Therapeutic drug monitoring for triazoles. <i>Current Opinion in Infectious Diseases</i> , 2008 , 21, 580-6	5.4	106
16	The pharmacology and clinical use of caspofungin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 263-74	5.5	24
15	Galactomannan antigen detection in the diagnosis of invasive aspergillosis. <i>Expert Review of Molecular Diagnostics</i> , 2007 , 7, 21-32	3.8	50
14	Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3760-2	5.9	20
13	Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3714-9	5.9	85
12	Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 285-95	5.9	34
11	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1031-9	11.6	2
10	Derivation of an in vivo drug exposure breakpoint for flucytosine against <i>Candida albicans</i> and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3680-8	5.9	33
9	Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of <i>Aspergillus fumigatus</i> in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 2475-80	9.7	66
8	Laboratory diagnosis of invasive aspergillosis. <i>Lancet Infectious Diseases</i> , 2005 , 5, 609-22	25.5	378
7	A PCR method for the identification of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) from screening swabs. <i>Pathology</i> , 2004 , 36, 265-8	1.6	12
6	Molecular mechanisms of primary resistance to flucytosine in <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4377-86	5.9	109
5	Optimising antifungal therapy for individual patients. <i>Internal Medicine Journal</i> , 2004 , 34, 147-9	1.6	5
4	Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. <i>Journal of Infection</i> , 2004 , 49, 136-40	18.9	5

3	Sequential infection with <i>Nocardia farcinica</i> and <i>Cryptococcus neoformans</i> var. <i>gattii</i> in an immunocompetent host. <i>Journal of Infection</i> , 2003 , 47, 256-9	18.9	3
2	Increase in prevalence of nosocomial non- <i>Candida albicans</i> candidaemia and the association of <i>Candida krusei</i> with fluconazole use. <i>Journal of Hospital Infection</i> , 2002 , 50, 56-65	6.9	104
1	Urine D-arabinitol/L-arabinitol ratio in diagnosing <i>Candida</i> infection in patients with haematological malignancy and HIV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002 , 42, 39-42	2.9	7